Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability
Nanomedicine Research Journal · 2026-03 · 11 (1) · 84-104
DOI: 10.22034/nmrj.2026.01.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomedicine Research Journal, 2026-03. Verfasst von Mohadeseh Madadi und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Olanzapine-loaded solid lipid nanoparticles coated with polycaprolactone (PCL@OLZ-SLNs) were created as a ligand-free method for long-term oral olanzapine (OLZ) distribution. A three-level Box-Behnken design was used to improve uncoated OLZ-SLNs, screening five solid lipids and three formulation factors (lipid-to-drug ratio 10–30, Tween 80 concentration 1–2% w/v, sonication period 60–120 s). Based on stearic acid (lipid-to-drug ratio 15:1, 1.5% Tween 80, 90 s sonication), the best uncoated formulation showed a particle size of 168.5 ± 4.1 nm, zeta potential –30.1 ± 1.2 mV, entrapment efficiency 92.4 ± 1.8%, drug loading 7.4 ± 0.3%, and PDI 0.151 ± 0.012.With just 61.3 ± 2.6% released in 24 hours and >88% over 7 days via a non-Fickian mechanism with little burst effect, coating with 3% w/v PCL significantly slowed drug release and increased particle size to 223.7 ± 18.4 nm. In comparison to uncoated SLNs, oral administration of PCL@OLZ-SLNs to Sprague-Dawley rats (10 mg/kg) significantly delayed Tmax from ~1 h to ~2 h, increased Cmax 3.15-fold, extended elimination half-life from ~4.5 h to ~6 h, and enhanced AUC₀₋∞ approximately 5-fold (from 12.45 ± 0.15 to 62.90 ± 0.24 µg·h/mL; p < 0.001).All things considered, this simple, scalable, ligand-free approach provides good biocompatibility and a workable path to oral olanzapine medication at longer intervals (e.g., once weekly), which may enhance patient adherence in the treatment of schizophrenia.
Schlagwörter
Zitieren
APA
Madadi, M., & Bagheri, G. (2026). Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability. Nanomedicine Research Journal, 11(1), 84-104. https://doi.org/10.22034/nmrj.2026.01.009
Vancouver
Madadi M, Bagheri G. Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability. Nanomedicine Research Journal. 2026;11(1):84-104. doi:10.22034/nmrj.2026.01.009
BibTeX
@article{Madadi2026,
author = {Madadi, Mohadeseh and Bagheri, Gita},
title = {Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability},
journal = {Nanomedicine Research Journal},
year = {2026},
volume = {11},
number = {1},
pages = {84--104},
doi = {10.22034/nmrj.2026.01.009}
}
EUVIMED